Actitrexx raises €3.5M Series A round
2 March 2021· Mainz, Germany· health, biotech, cell_therapy, b2b, deep_hardware
The company plans to use the funds to further optimize and clinically test its novel cell therapy ATreg, with first clinical trials aimed at leukemia patients undergoing stem cell transplantation at risk of graft-versus-host disease (GvHD).
Investors
LeadLBBW Venture Capital
Also participating
High-Tech GründerfondsInvestitions- und Strukturbank Rheinland-PfalzMediVentures
About Actitrexx
Stage
Seed
Headquarters
Mainz, Germany
Founded
2020
Team Size
6–20
Sectors
healthbiotechcell_therapyb2bdeep_hardware
Source: https://www.finsmes.com/2021/03/actitrexx-raises-e3-5m-in-series-a-funding.html